JP2006520323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006520323A5 JP2006520323A5 JP2005508613A JP2005508613A JP2006520323A5 JP 2006520323 A5 JP2006520323 A5 JP 2006520323A5 JP 2005508613 A JP2005508613 A JP 2005508613A JP 2005508613 A JP2005508613 A JP 2005508613A JP 2006520323 A5 JP2006520323 A5 JP 2006520323A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- cancer
- conjugate
- group
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 39
- 102000003996 Interferon-beta Human genes 0.000 claims 34
- 108090000467 Interferon-beta Proteins 0.000 claims 34
- 229960001388 interferon-beta Drugs 0.000 claims 34
- 229920001515 polyalkylene glycol Polymers 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 229920000642 polymer Polymers 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 10
- 229940024606 amino acid Drugs 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 238000003556 assay Methods 0.000 claims 9
- 108010005714 Interferon beta-1b Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 229960003161 interferon beta-1b Drugs 0.000 claims 8
- 235000018102 proteins Nutrition 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000004113 cell culture Methods 0.000 claims 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 5
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 5
- 229920003169 water-soluble polymer Polymers 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 230000000975 bioactive effect Effects 0.000 claims 4
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 238000002832 anti-viral assay Methods 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003593 megakaryocyte Anatomy 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 238000007248 oxidative elimination reaction Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000036961 partial effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000024335 physical disease Diseases 0.000 claims 2
- -1 poly (oxyethylene-oxymethylene) Polymers 0.000 claims 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims 2
- 229920005646 polycarboxylate Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 2
- 230000000506 psychotropic effect Effects 0.000 claims 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 2
- 238000003567 signal transduction assay Methods 0.000 claims 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000000149 argon plasma sintering Methods 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- SSTZWBSEDRHYPU-UHFFFAOYSA-L barium(2+);diperiodate Chemical compound [Ba+2].[O-]I(=O)(=O)=O.[O-]I(=O)(=O)=O SSTZWBSEDRHYPU-UHFFFAOYSA-L 0.000 claims 1
- JOOPRXVUNTUGSV-UHFFFAOYSA-L calcium;diperiodate Chemical compound [Ca+2].[O-]I(=O)(=O)=O.[O-]I(=O)(=O)=O JOOPRXVUNTUGSV-UHFFFAOYSA-L 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003797 essential amino acid Substances 0.000 claims 1
- 235000020776 essential amino acid Nutrition 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-M periodate Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 claims 1
- FJVZDOGVDJCCCR-UHFFFAOYSA-M potassium periodate Chemical compound [K+].[O-]I(=O)(=O)=O FJVZDOGVDJCCCR-UHFFFAOYSA-M 0.000 claims 1
- 239000012460 protein solution Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000005932 reductive alkylation reaction Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- 238000005199 ultracentrifugation Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43602002P | 2002-12-26 | 2002-12-26 | |
| US60/436,020 | 2002-12-26 | ||
| US47991303P | 2003-06-20 | 2003-06-20 | |
| US47991403P | 2003-06-20 | 2003-06-20 | |
| US60/479,913 | 2003-06-20 | ||
| US60/479,914 | 2003-06-20 | ||
| PCT/US2003/041160 WO2004060299A2 (en) | 2002-12-26 | 2003-12-23 | Polymer conjugates of interferon-beta with enhanced biological potency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012138434A Division JP2012232984A (ja) | 2002-12-26 | 2012-06-20 | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006520323A JP2006520323A (ja) | 2006-09-07 |
| JP2006520323A5 true JP2006520323A5 (enExample) | 2007-02-15 |
| JP5207590B2 JP5207590B2 (ja) | 2013-06-12 |
Family
ID=32719161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005508613A Expired - Fee Related JP5207590B2 (ja) | 2002-12-26 | 2003-12-23 | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
| JP2012138434A Withdrawn JP2012232984A (ja) | 2002-12-26 | 2012-06-20 | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012138434A Withdrawn JP2012232984A (ja) | 2002-12-26 | 2012-06-20 | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9125880B2 (enExample) |
| EP (1) | EP1667708B9 (enExample) |
| JP (2) | JP5207590B2 (enExample) |
| KR (1) | KR101238517B1 (enExample) |
| CN (1) | CN102319437B (enExample) |
| AU (1) | AU2003303635B2 (enExample) |
| BR (1) | BR0317742A (enExample) |
| CA (1) | CA2511814C (enExample) |
| CR (1) | CR7894A (enExample) |
| CY (1) | CY1113281T1 (enExample) |
| DK (1) | DK1667708T5 (enExample) |
| EA (1) | EA008866B1 (enExample) |
| EC (1) | ECSP055930A (enExample) |
| ES (1) | ES2389183T3 (enExample) |
| GE (1) | GEP20084486B (enExample) |
| IL (1) | IL169391A (enExample) |
| IS (1) | IS7932A (enExample) |
| MX (1) | MXPA05006944A (enExample) |
| NO (1) | NO339917B1 (enExample) |
| NZ (1) | NZ541124A (enExample) |
| PL (1) | PL219741B1 (enExample) |
| PT (1) | PT1667708E (enExample) |
| RS (1) | RS20050502A (enExample) |
| TW (1) | TWI406672B (enExample) |
| WO (1) | WO2004060299A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| MXPA04006855A (es) | 2002-01-18 | 2005-04-19 | Biogen Idec Inc | Compuestos de polimeros de polialquileno y usos de los mismos. |
| US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| US9599619B2 (en) | 2002-06-14 | 2017-03-21 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| US8821868B2 (en) | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| CA2511815A1 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| CN102212019B (zh) | 2003-03-14 | 2015-05-27 | 蔚所番有限公司 | 支化水溶性聚合物及其缀合物 |
| MXPA05010411A (es) * | 2003-03-28 | 2006-05-31 | Biopolymed Inc | Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen. |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| EP1625156B1 (en) | 2003-05-12 | 2012-09-19 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| EP1626983B8 (en) * | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| JP2007500218A (ja) | 2003-05-12 | 2007-01-11 | アフィーマックス・インコーポレイテッド | ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分 |
| US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| ES2447423T3 (es) * | 2003-08-29 | 2014-03-12 | Dyax Corp. | Inhibidores de proteasa poli-pegilados |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| JP5743368B2 (ja) | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | ペプチドのｏ結合型グリコシル化 |
| CA2556339A1 (en) * | 2004-03-01 | 2005-09-15 | David Ray Filpula | Interferon-beta polymer conjugates |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| US7642072B2 (en) * | 2004-07-26 | 2010-01-05 | Enzon Pharmaceuticals, Inc. | Optimized interferon-beta gene |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| KR20070108140A (ko) * | 2004-11-11 | 2007-11-08 | 아피맥스, 인크. | 에리트로포이에틴 수용체에 결합하는 신규한 펩타이드 |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US8067006B2 (en) | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
| EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| CA2627939A1 (en) * | 2005-12-15 | 2007-06-21 | Laboratoires Serono S.A. | New chemokine antagonists |
| WO2007116410A2 (en) * | 2006-04-11 | 2007-10-18 | Mileutis Ltd. | Livestock management for improved reproductive efficiency |
| US7632492B2 (en) | 2006-05-02 | 2009-12-15 | Allozyne, Inc. | Modified human interferon-β polypeptides |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| AU2007343610C1 (en) * | 2007-01-17 | 2013-11-07 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| RS52845B (sr) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | Postupci tretmana korišćenjem glikopegiliranog g-csf |
| WO2008137471A2 (en) * | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | ヌクレオチド糖の改良製造法 |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| WO2009026334A2 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| CN101878043A (zh) | 2007-12-20 | 2010-11-03 | 默克雪兰诺有限公司 | PEG-干扰素-β制剂 |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| WO2011091113A2 (en) * | 2010-01-22 | 2011-07-28 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
| WO2010023670A2 (en) * | 2008-08-28 | 2010-03-04 | Insight Biopharmaceuticals Ltd. | Methods for covalently attaching a polymer to a methionine residue in proteins and peptides |
| MX2011003117A (es) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
| US20110171161A1 (en) | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
| DE102009032179A1 (de) * | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
| WO2012044684A2 (en) * | 2010-10-01 | 2012-04-05 | Biogen Idec Ma Inc. | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
| KR101309566B1 (ko) * | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| EP2675485A4 (en) | 2011-02-15 | 2014-10-15 | Immunomedics Inc | ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER |
| EP2854845B1 (en) | 2012-06-01 | 2018-03-28 | IBC Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9452228B2 (en) | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
| WO2015065987A1 (en) | 2013-11-01 | 2015-05-07 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| JP2017529837A (ja) | 2014-09-03 | 2017-10-12 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
| EP3303370A4 (en) | 2015-05-28 | 2019-03-13 | Immunomedics, Inc. | T20-CONSTRUCTS FOR THERAPY AND / OR VACCINES AGAINST HIV (HUMAN IMMUNODEFICIENCY VIRUS) |
| CN116077648A (zh) | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| EP3664856A4 (en) * | 2017-08-07 | 2021-04-28 | The University of Akron | POLY (ESTER-UREA) FOR MEMORY AND DRUG ADMINISTRATION |
| CN109400695B (zh) * | 2018-10-31 | 2020-06-30 | 中南大学湘雅医院 | 一种多肽的修饰方法及应用 |
| US20230272001A1 (en) * | 2020-05-22 | 2023-08-31 | Merck Sharp & Dohme Llc | Novel processes for preparing conjugates of the il-2 protein |
| TWI888659B (zh) * | 2021-10-13 | 2025-07-01 | 芯芮生技開發股份有限公司 | 幹細胞條件培養基於製備抑制癌症組成物的用途 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| GB1578348A (en) * | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
| JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| GR81946B (enExample) | 1980-09-25 | 1984-12-12 | Genentech Inc | |
| US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| WO1985003934A1 (fr) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Proteine modifiee chimiquement et son procede de preparation |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| US4816440A (en) * | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
| US5037969A (en) * | 1986-07-03 | 1991-08-06 | Takeda Chemical Industries, Ltd. | Glycosyl derivatives and use thereof |
| US4894330A (en) * | 1986-12-23 | 1990-01-16 | Cetus Corporation | Purification of recombinant beta-interferon incorporating RP-HPLC |
| US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
| IE64284B1 (en) | 1987-08-03 | 1995-07-26 | Ddi Pharmaceuticals | Conjugates of superoxide dismutase |
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5006333A (en) * | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
| US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
| US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| EP0458064B1 (en) | 1990-05-04 | 1998-02-25 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues |
| US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| JP3051145B2 (ja) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5362852A (en) * | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| US5221676A (en) * | 1992-02-06 | 1993-06-22 | Warner-Lambert Company | 7-substituted quinolones and naphthyridones as antibacterial agents |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| CA2101361A1 (en) * | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
| US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| ATE214940T1 (de) * | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| JP2996415B2 (ja) * | 1994-03-31 | 1999-12-27 | アムジエン・インコーポレーテツド | 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド |
| JP3173794B2 (ja) * | 1994-05-20 | 2001-06-04 | 久光製薬株式会社 | タンパク質またはポリペプチド類とその製造法および中間化合物 |
| EP0756494A1 (en) | 1994-05-24 | 1997-02-05 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5756593A (en) * | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
| WO1996040731A1 (en) | 1995-06-07 | 1996-12-19 | Mount Sinai School Of Medicine Of The City University Of New York | Pegylated modified proteins |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| DE69736780T2 (de) * | 1996-08-02 | 2007-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| WO2000042175A1 (en) | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
| EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US6017876A (en) * | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| DE69921102T2 (de) * | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
| US6455639B1 (en) * | 1998-03-24 | 2002-09-24 | Nof Corporation | Oxirane derivative and process for the preparation thereof |
| NZ507456A (en) | 1998-04-28 | 2003-10-31 | Applied Research Systems | Process and conjugated forms of PEGylated interferon- beta with polyethylene glycol (PEG) wherein the thiol reactive polyol agent is mono-methoxylated |
| ATE366114T1 (de) | 1998-05-12 | 2007-07-15 | Greenville Hospital System | Verwendung von anti-prolaktin agentien zur behandlung von krebs |
| US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| CA2338665C (en) * | 1998-08-06 | 2011-01-18 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| AU762616B2 (en) * | 1998-10-16 | 2003-07-03 | Biogen Ma Inc. | Polymer conjugates of interferon beta-1a and uses |
| JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| US7431921B2 (en) * | 1999-08-27 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
| US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
| BR0013638A (pt) * | 1999-08-27 | 2002-05-14 | Maxygen Aps | Novas moléculas semelhantes a interferon beta |
| ATE522563T1 (de) | 1999-12-24 | 2011-09-15 | Kyowa Hakko Kirin Co Ltd | Verzweigte polyalkylenglykole |
| NZ522847A (en) | 2000-05-16 | 2004-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| AR032757A1 (es) | 2000-06-30 | 2003-11-26 | Smithkline Beecham Corp | Composiciones biologicamente activas de conjugados de quimioquina, uso de dichas composiciones en la fabricacion de composiciones farmaceuticas, metodo para preparar dichas composiciones, y metodos para mejorar la farmacocinetica de una quimioquina |
| ATE421535T1 (de) * | 2000-10-16 | 2009-02-15 | Chugai Pharmaceutical Co Ltd | Peg-modifiziertes erythropoietin |
| ATE505204T1 (de) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| AU2002305914A1 (en) * | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
| JP2004534523A (ja) * | 2001-02-27 | 2004-11-18 | マキシゲン・エイピーエス | 新規なインターフェロンβ様分子 |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| MXPA03011793A (es) | 2001-06-29 | 2004-04-02 | Maxygen Holdings Ltd | Formulaciones de interferon. |
| US6908963B2 (en) * | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| AU2002346686A1 (en) | 2001-12-07 | 2003-06-23 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
| EP1507755A4 (en) | 2001-12-11 | 2006-05-17 | Sun Bio Inc | NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES |
| MXPA04006855A (es) * | 2002-01-18 | 2005-04-19 | Biogen Idec Inc | Compuestos de polimeros de polialquileno y usos de los mismos. |
| AU2003256613A1 (en) | 2002-07-19 | 2004-02-09 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
| AU2003254641A1 (en) | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| GEP20074193B (en) * | 2002-09-09 | 2007-09-10 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
| US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| WO2004046365A2 (en) | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US8828373B2 (en) * | 2002-11-20 | 2014-09-09 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
| US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
| TWI281864B (en) * | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
| CA2511815A1 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| WO2004089421A2 (en) | 2003-03-31 | 2004-10-21 | Xencor, Inc | Methods for rational pegylation of proteins |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| CA2556339A1 (en) | 2004-03-01 | 2005-09-15 | David Ray Filpula | Interferon-beta polymer conjugates |
| RU2298560C2 (ru) | 2004-04-30 | 2007-05-10 | Открытое Акционерное Общество "Верофарм" | Конъюгаты белка и производного полиэтиленгликоля, фармацевтическая композиция, способ борьбы с вирусной инфекцией |
| JP2009524598A (ja) * | 2005-12-30 | 2009-07-02 | ファーマエッセンティア コーポレイション | 薬剤−高分子結合体 |
-
2003
- 2003-12-23 WO PCT/US2003/041160 patent/WO2004060299A2/en not_active Ceased
- 2003-12-23 TW TW92136583A patent/TWI406672B/zh not_active IP Right Cessation
- 2003-12-23 PL PL379987A patent/PL219741B1/pl unknown
- 2003-12-23 RS YUP20050502 patent/RS20050502A/sr unknown
- 2003-12-23 CN CN201110224336.2A patent/CN102319437B/zh not_active Expired - Fee Related
- 2003-12-23 EA EA200501050A patent/EA008866B1/ru not_active IP Right Cessation
- 2003-12-23 ES ES03808554T patent/ES2389183T3/es not_active Expired - Lifetime
- 2003-12-23 MX MXPA05006944A patent/MXPA05006944A/es active IP Right Grant
- 2003-12-23 DK DK03808554T patent/DK1667708T5/da active
- 2003-12-23 BR BR0317742A patent/BR0317742A/pt not_active Application Discontinuation
- 2003-12-23 KR KR20057012126A patent/KR101238517B1/ko not_active Expired - Fee Related
- 2003-12-23 NZ NZ541124A patent/NZ541124A/en not_active IP Right Cessation
- 2003-12-23 EP EP20030808554 patent/EP1667708B9/en not_active Revoked
- 2003-12-23 PT PT03808554T patent/PT1667708E/pt unknown
- 2003-12-23 CA CA 2511814 patent/CA2511814C/en not_active Expired - Fee Related
- 2003-12-23 GE GEAP2003008910 patent/GEP20084486B/en unknown
- 2003-12-23 JP JP2005508613A patent/JP5207590B2/ja not_active Expired - Fee Related
- 2003-12-23 AU AU2003303635A patent/AU2003303635B2/en not_active Ceased
- 2003-12-23 US US10/743,068 patent/US9125880B2/en not_active Expired - Fee Related
-
2005
- 2005-06-26 IL IL169391A patent/IL169391A/en active IP Right Grant
- 2005-07-04 CR CR7894A patent/CR7894A/es unknown
- 2005-07-04 IS IS7932A patent/IS7932A/is unknown
- 2005-07-20 EC ECSP055930 patent/ECSP055930A/es unknown
- 2005-07-20 NO NO20053556A patent/NO339917B1/no not_active IP Right Cessation
-
2012
- 2012-06-20 JP JP2012138434A patent/JP2012232984A/ja not_active Withdrawn
- 2012-09-05 CY CY20121100796T patent/CY1113281T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006520323A5 (enExample) | ||
| JP4157277B2 (ja) | 実質的に純粋なヒスチジン結合タンパク質−ポリマー結合体 | |
| KR100607388B1 (ko) | 개선된 인터페론 중합체 접합체 | |
| US5711944A (en) | Interferon polymer conjugates | |
| JP5123201B2 (ja) | タンパク質及びペプチドに対する結合のための４分枝デンドリマー−ｐｅｇ | |
| JP2637010B2 (ja) | ポリエチレンタンパク質接合体 | |
| KR100203824B1 (ko) | 거핵구 성장 및 분화를 자극하기 위한 조성물 및방법 | |
| JP4474521B2 (ja) | チオエステル末端化水溶性ポリマーおよびそれを用いてポリペプチドのｎ末端を改変する方法 | |
| JPH09504515A (ja) | ポリマー変性 | |
| JP2007520223A5 (enExample) | ||
| CN1211578A (zh) | 聚乙二醇－干扰素结合物 | |
| CA2617064A1 (en) | Conjugates of a g-csf moiety and a polymer | |
| RU2010106430A (ru) | Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение | |
| KR20060135887A (ko) | 신규의 ｇ-ｃｓｆ 콘쥬게이트 | |
| US12448488B2 (en) | Conjugate of bio-related substance and block polymer, and block polymer derivative for obtaining said conjugate | |
| KR100480430B1 (ko) | 인터페론-베타와 폴리에틸렌글리콜 유도체의 배합체 |